Tenon Medical Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for the use of their Catamaran® SI Joint Fusion System. This approval allows the system to be used to augment immobilization and stabilization of the sacroiliac (SI) joint for patients undergoing sacropelvic fixation as part of a lumbar fusion. The company believes this regulatory milestone will open a substantial new market opportunity by addressing the need for robust SI joint stabilization in complex spinal fusion procedures. This expanded indication aims to enhance patient care for those suffering from SI joint disorders by providing a dependable and efficient method for authentic SI joint fusion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.